Popular Trials
Cell Therapy
cSVF Therapy for Post-COVID Lung Damage
This trial is a study to test a possible treatment for people who have lung damage from the COVID-19 virus. The treatment involves taking cells from the patient's own body and injecting them into the patient's bloodstream. The goal is to see if this can help improve the function of the lungs.
Stem Cell Therapy
MultiStem for COVID-19 Induced ARDS
This trial is testing MultiStem therapy, which uses special cells to help heal and reduce inflammation, in patients with moderate to severe ARDS, including those caused by COVID-19. The therapy aims to calm the body's response and support lung repair. MultiStem therapy has shown promise in reducing inflammation and aiding lung repair in severe COVID-19 cases.
Popular Filters
Trials for Coronavirus Patients
Behavioural Intervention
Motivational Support for Physical Activity in Heart Disease
This trial is testing whether a new program called "Heart Up!" can help people with heart disease who feel hopeless. The program uses text messages to motivate patients to be more physically active. The goal is to see if this increases physical activity and reduces hopelessness.
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Trials for Coronavirus Infection Patients
Device
FreeO2 for Coronavirus Infection
There is a high risk of transmission of COVID-19 to healthcare workers. In a recent cohort, 29% of the patients hospitalized were healthcare workers. Among the WHO's primary strategic objectives for the response to COVID-19, the first was to limit human-to-human transmission, including reducing secondary infections among close contacts and health care workers. Automated oxygen titration, weaning and monitoring (FreeO2 device) may be a solution to reduce the number of interventions of healthcare workers related to oxygen therapy, to reduce complications related to oxygen and to improve monitoring.
Diagnostic Test
COVID-19 Antigen/Antibody Rapid Testing for Coronavirus
This trial assesses the clinical accuracy of rapid COVID-19 diagnostic tests compared to a reference test, and whether self-testing with mobile device imaging and telemedicine support is as accurate and safe as testing in a clinical setting. Antibodies to SARS-CoV-2 are also being tested after diagnosis or vaccination.
Phase 3 Trials
Virus Therapy
DAS181 for Respiratory Infections
This trial will enroll immunocompromised patients with Lower Tract parainfluenza infection to study the safety and efficacy of an investigational vaccine. A sub-study will also enroll patients with severe COVID-19.
Corticosteroid
Multiple Treatments for COVID-19
This trial tests various drugs on hospitalized COVID-19 patients to see if they work better than standard treatments. The drugs aim to reduce inflammation, block harmful proteins, or kill viruses. Remdesivir has been studied extensively for its antiviral properties and was initially developed for treating Ebola virus.
Neurokinin-1 Receptor Antagonist
Tradipitant for Coronavirus
This is a randomized, double-blind placebo-controlled trial to investigate the efficacy and safety of tradipitant 85 mg orally given twice daily to treat inflammatory lung injury associated with severe or critical COVID-19 infection. On evaluation for enrollment, participant will need to meet all inclusion and exclusion criteria. If participant consents, they will be randomized 1:1 to treatment with either tradipitant 85 mg PO BID or placebo in addition to standard of care for COVID-19 infection as per the protocol at the treating hospital. NEWS 2 will be assessed at screening and daily following randomization. Inflammatory lab markers as detailed should be collected once per day in the morning, preferably at the same time every morning. All enrolled participants will have whole blood collected for whole genome sequencing.
Lopinavir/ritonavir for Coronavirus
This trial is testing whether lopinavir/ritonavir can prevent people from getting COVID-19. The trial will help generate key data on COVID-19 transmission and serve as a research platform for future vaccines and preventive agents.
Trials With No Placebo
Procedure
Splenic Ultrasound for Long COVID
This trial is testing a new treatment for Long COVID using a small device that sends sound waves to the spleen. The goal is to see if this can reduce inflammation and improve symptoms in patients who have had ongoing issues after their initial COVID-19 infection.
Procedure
Ventilation Strategy for Acute Respiratory Distress Syndrome
This trial tests if adjusting ventilator settings based on lung measurements can reduce deaths in ARDS patients, including those with COVID-19. The goal is to provide better breathing support without causing more lung damage.
Behavioural Intervention
Motivational Support for Physical Activity in Heart Disease
This trial is testing whether a new program called "Heart Up!" can help people with heart disease who feel hopeless. The program uses text messages to motivate patients to be more physically active. The goal is to see if this increases physical activity and reduces hopelessness.
View More Related Trials
Frequently Asked Questions
Introduction to covid
What are the top hospitals conducting covid research?
In the global battle against COVID-19, top hospitals have emerged as beacons of hope and innovation. One such institution is the University of Rochester Medical Center in Rochester, New york. Despite their relatively small number of active COVID trials (3) and all-time trials (2), this hospital has made significant strides since recording its first trial in 2020. Similarly, the University of South Florida in Tampa has dedicated itself to finding effective solutions with three ongoing COVID trials and a history of two previous studies. Both these facilities have demonstrated their commitment to pushing boundaries and exploring new avenues for treatment.
Meanwhile, Hennepin County Medical Center located in Minneapolis has also stepped up to face this unprecedented challenge head-on. With three active COVID trials underway and four completed studies under its belt, this medical center stands at the forefront of innovative research within their community since initiating their inaugural trial last year.
The University of Minnesota - another prominent institution nestled in Minneapolis - joins forces by conducting three concurrent clinical trials focused on combating COVID-19 while boasting an impressive ten past investigations centered around the virus's impact on public health; they too started contributing towards understanding it from 2020 onwards.
Notably making an appearance among these renowned hospitals is Massachusetts General Hospital situated in Boston—the city rich with medical excellence—where doctors and researchers are actively engaged in three cutting-edge clinical trials aimed at conquering the pandemic that has gripped our world tightly. Having previously conducted five additional studies related to COVID-19 since embarking on research endeavors just last year.
These hospitals exemplify unwavering dedication and perseverance in tackling the current crisis. The incredible work being done across these institutions signifies extraordinary collaboration between healthcare professionals, scientists, volunteers, patients, who collectively strive for a brighter future amidst uncertain times
Which are the best cities for covid clinical trials?
When it comes to COVID clinical trials, several cities stand out as leaders in research and development. Houston, Texas leads the way with 27 active trials focusing on mRNA-1273 and Biological/Vaccine: BNT162b2 3mcg among others. Miami, Florida follows closely behind with 20 ongoing studies exploring PBI-0451 (Pomotrelvir) and Niclosamide, among other treatments. New york, New York also plays a significant role with 18 active trials investigating various treatment options like Cohort B, Arm B2P: BNT162b2 and Therapeutic Dose Anticoagulation + P2Y12 inhibitor. Additionally, Los Angeles, California and Atlanta, Georgia have notable contributions to COVID clinical trials with their respective studies on ritonavir and Biological/Vaccine: BNT162b2 3mcg. These cities collectively provide individuals affected by COVID access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in combating the virus.
Which are the top treatments for covid being explored in clinical trials?
Clinical trials are actively investigating potential treatments for COVID-19, with several options showing promise. Hydroxychloroquine is currently being explored in two active trials and has been part of 22 clinical trials overall since its first listing in 2020. Another treatment gaining attention is VBI-2901a, which has one ongoing trial and was introduced to COVID research in 2022. These treatments offer hope as researchers work diligently to combat the impact of this global pandemic.
What are the most recent clinical trials for covid?
Exciting advancements are underway in the field of COVID-19 research, with recent clinical trials offering potential breakthroughs in our fight against this global pandemic. Noteworthy studies include Group i, a Phase 4 trial that aims to evaluate the effectiveness of a specific intervention for COVID-19 patients. Additionally, an inspiring Phase 1 trial investigates the use of allogeneic mesenchymal stromal cells as a treatment option for COVID-19. Another significant study involves individuals who have undergone solid organ transplants and examines their response to COVID-19 treatments in a Phase 2 trial. Further progress can be seen through Group 2 and Active, both undergoing Phase 2 trials to assess their efficacy in combatting this infectious disease. With these diverse approaches being investigated, there is hope on the horizon for improved outcomes and ultimately overcoming the challenges posed by COVID-19.
What covid clinical trials were recently completed?
Several clinical trials focusing on COVID-19 have recently concluded, representing vital steps forward in our fight against the pandemic. In August 2021, Merck Sharp & Dohme Corp. completed a trial for Molnupiravir, while Janssen Vaccines & Prevention B.V.'s Ad26.COV2.S trial also reached completion during the same month. Earlier in July 2021, James L. Kirkland's Fisetin study made significant progress as well. These trials build upon the substantial research conducted to combat COVID-19 and provide valuable insights into potential treatments and preventive measures.